Yu Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yu Chen has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Gerhard Wolber
Molecular Design Group, Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy Freie Universität Berlin Berlin Germany
3 shared publications - Valerij Talagayev
Freie Universität Berlin
3 shared publications - Clemens Alexander Wolf
Pharmaceutical and Medicinal Chemistry (Computer-Aided Drug Design), Institute of Pharmacy
2 shared publications - Katrin Denzinger
Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Straße 2+4, D-14195 Berlin, Germany
2 shared publications - Kristina Puls
Department of Biology, Chemistry and Pharmacy, Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Str. 2+4, 14195 Berlin, Germany
2 shared publications - Sijie Liu
Freie Universität Berlin
2 shared publications
Latest Publications
- Open Access
- 1 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
CACHE Challenge #3: Targeting the Nsp3 Macrodomain of SARS-CoV-2
The third Critical Assessment of Computational Hit-finding Experiments (CACHE) challenged computational teams to identify chemically novel ligands targeting the macrodomain 1 of SARS-CoV-2 Nsp3, a promising coronavirus drug target. Twenty-three groups deployed diverse design strategies to collectively select 1739 ligand candidates. While over 85% of the designed molecules were chemically novel, the best experimentally confirmed hits were structurally similar to previously published compounds. Confirming a trend observed in CACHE #1 and #2, two of the best-performing workflows used compounds selected by physics-based computational screening methods to train machine learning models able to rapidly screen large chemical libraries, while four others used exclusively physics-based approaches. Three pharmacophore searches and one fragment growing strategy were also part of the seven winning workflows. While active molecules discovered by CACHE #3 participants largely mimicked the adenine ring of the endogenous substrate, ADP-ribose, preserving the canonical chemotype commonly observed in previously reported Nsp3-Mac1 ligands, they still provide novel structure-activity relationship insights that may inform the development of future antivirals. Collectively, these results show that multiple molecular design strategies can efficiently converge on similar effective molecules.
- 1 October 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessCACHE Challenge #3: Targeting the Nsp3 Macrodomain of SARS-CoV-2
The third Critical Assessment of Computational Hit-finding Experiments (CACHE) challenged computational teams to identify chemically novel ligands targeting the macrodomain 1 of SARS-CoV-2 Nsp3, a promising coronavirus drug target. Twenty-three groups deployed diverse design strategies to collectively select 1739 ligand candidates. While over 85% of the designed molecules were chemically novel, the best experimentally confirmed hits were structurally similar to previously published compounds. Confirming a trend observed in CACHE #1 and #2, two of the best-performing workflows used compounds selected by physics-based computational screening methods to train machine learning models able to rapidly screen large chemical libraries, while four others used exclusively physics-based approaches. Three pharmacophore searches and one fragment growing strategy were also part of the seven winning workflows. While active molecules discovered by CACHE #3 participants largely mimicked the adenine ring of the endogenous substrate, ADP-ribose, preserving the canonical chemotype commonly observed in previously reported Nsp3-Mac1 ligands, they still provide novel structure-activity relationship insights that may inform the development of future antivirals. Collectively, these results show that multiple molecular design strategies can efficiently converge on similar effective molecules.
- Open Access
- 22 October 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (11) , 1304
Mind the Gap—Deciphering GPCR Pharmacology Using 3D Pharmacophores and Artificial Intelligence
G protein-coupled receptors (GPCRs) are amongst the most pharmaceutically relevant and well-studied protein targets, yet unanswered questions in the field leave significant gaps in our understanding of their nuanced structure and function. Three-dimensional pharmacophore models are powerful computational tools in in silico drug discovery, presenting myriad opportunities for the integration of GPCR structural biology and cheminformatics. This review highlights success stories in the application of 3D pharmacophore modeling to de novo drug design, the discovery of biased and allosteric ligands, scaffold hopping, QSAR analysis, hit-to-lead optimization, GPCR de-orphanization, mechanistic understanding of GPCR pharmacology and the elucidation of ligand–receptor interactions. Furthermore, advances in the incorporation of dynamics and machine learning are highlighted. The review will analyze challenges in the field of GPCR drug discovery, detailing how 3D pharmacophore modeling can be used to address them. Finally, we will present opportunities afforded by 3D pharmacophore modeling in the advancement of our understanding and targeting of GPCRs.
- 22 October 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (11) , 1304
Open AccessMind the Gap—Deciphering GPCR Pharmacology Using 3D Pharmacophores and Artificial Intelligence
G protein-coupled receptors (GPCRs) are amongst the most pharmaceutically relevant and well-studied protein targets, yet unanswered questions in the field leave significant gaps in our understanding of their nuanced structure and function. Three-dimensional pharmacophore models are powerful computational tools in in silico drug discovery, presenting myriad opportunities for the integration of GPCR structural biology and cheminformatics. This review highlights success stories in the application of 3D pharmacophore modeling to de novo drug design, the discovery of biased and allosteric ligands, scaffold hopping, QSAR analysis, hit-to-lead optimization, GPCR de-orphanization, mechanistic understanding of GPCR pharmacology and the elucidation of ligand–receptor interactions. Furthermore, advances in the incorporation of dynamics and machine learning are highlighted. The review will analyze challenges in the field of GPCR drug discovery, detailing how 3D pharmacophore modeling can be used to address them. Finally, we will present opportunities afforded by 3D pharmacophore modeling in the advancement of our understanding and targeting of GPCRs.
- Open Access
- 14 September 2022
- Published by MDPI AG in Preprints.org
Mind the Gap – Deciphering GPCR Pharmacology Using 3D Pharmacophores and Artificial Intelligence
G protein-coupled receptors (GPCRs) are amongst the most pharmaceutically relevant and well-studied protein targets, yet unanswered questions in the field leave significant gaps in our understanding of their nuanced structure and function. 3D pharmacophore models are powerful computational tools in silico drug discovery, presenting myriad opportunities for the integration of GPCR structural biology and cheminformatics. This review highlights success stories in the application of 3D pharmacophore modeling to de novo drug design, discovery of biased and allosteric ligands, scaffold hopping, QSAR analysis, hit-to-lead optimization, GPCR de-orphanization, mechanistic understanding of GPCR pharmacology and elucidation of ligand-receptor interactions. Furthermore, advances in the incorporation of dynamics and machine learning will be highlighted. The review will analyze challenges in the field of GPCR drug discovery, detailing how 3D pharmacophore modeling can be used to address them. Finally, we will present opportunities afforded by 3D pharmacophore modeling in the advancement of our understanding and targeting of GPCRs.
- 14 September 2022
- Published by MDPI AG in Preprints.org
Open AccessMind the Gap – Deciphering GPCR Pharmacology Using 3D Pharmacophores and Artificial Intelligence
G protein-coupled receptors (GPCRs) are amongst the most pharmaceutically relevant and well-studied protein targets, yet unanswered questions in the field leave significant gaps in our understanding of their nuanced structure and function. 3D pharmacophore models are powerful computational tools in silico drug discovery, presenting myriad opportunities for the integration of GPCR structural biology and cheminformatics. This review highlights success stories in the application of 3D pharmacophore modeling to de novo drug design, discovery of biased and allosteric ligands, scaffold hopping, QSAR analysis, hit-to-lead optimization, GPCR de-orphanization, mechanistic understanding of GPCR pharmacology and elucidation of ligand-receptor interactions. Furthermore, advances in the incorporation of dynamics and machine learning will be highlighted. The review will analyze challenges in the field of GPCR drug discovery, detailing how 3D pharmacophore modeling can be used to address them. Finally, we will present opportunities afforded by 3D pharmacophore modeling in the advancement of our understanding and targeting of GPCRs.
- 17 April 2020
- Published by Royal Society of Chemistry (RSC) in Physical Chemistry Chemical Physics
- Vol. 22 (17) , 9656-9663
The application of the MM/GBSA method in the binding pose prediction of FGFR inhibitors
The correct conformation had lower MM/GBSA binding free energy in longer MD simulations for each FGFR1 inhibitor.
- 17 April 2020
- Published by Royal Society of Chemistry (RSC) in Physical Chemistry Chemical Physics
- Vol. 22 (17) , 9656-9663
The application of the MM/GBSA method in the binding pose prediction of FGFR inhibitors
The correct conformation had lower MM/GBSA binding free energy in longer MD simulations for each FGFR1 inhibitor.
- 11 February 2019
- Published by Taylor & Francis in Petroleum Science and Technology
- Vol. 37 (9) , 1053-1058
The performance comparison in predicting n-decane pyrolysis process between three ANNs methods: MLP, RBFN and GRNN
In this work, three kinds of ANNs are employed to predict the pyrolysis behavior of n-decane. Six-fold cross validation method is adopted to optimize the key parameter of ANNs and evaluate the performance of ANNs. The results indicate that RBFN has best performance in predicting the species distribution and all ANNs have good performance in predicting the bulk temperature. Meanwhile, these results reveal that all ANNs are more suitable for predicting products with high mass fraction than those with less mass fraction, whose errors are also acceptable.
- 11 February 2019
- Published by Taylor & Francis in Petroleum Science and Technology
- Vol. 37 (9) , 1053-1058
The performance comparison in predicting n-decane pyrolysis process between three ANNs methods: MLP, RBFN and GRNN
In this work, three kinds of ANNs are employed to predict the pyrolysis behavior of n-decane. Six-fold cross validation method is adopted to optimize the key parameter of ANNs and evaluate the performance of ANNs. The results indicate that RBFN has best performance in predicting the species distribution and all ANNs have good performance in predicting the bulk temperature. Meanwhile, these results reveal that all ANNs are more suitable for predicting products with high mass fraction than those with less mass fraction, whose errors are also acceptable.